Biotech startup GenEdit is developing polymer nanoparticle technology to deliver genetic medicines, an approach intended to avoid the limitations of viral vectors. Already partnered with a clinical-stage company, it now has financial support from a big pharma giant that joined a syndicate of investors in a $26 million Series A round.
While well-developed in cancers, precision medicine's readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Sarepta Therapeutics gains rights to University of Florida-resident startup's programs for central nervous system diseases.